" class="no-js "lang="en-US"> Nona Biosciences Enters into Agreement with ModeX Therapeutics
Monday, June 05, 2023

Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health’s ModeX Therapeutics

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from “Idea to IND” (I to ITM), today announced it has entered into an agreement with ModeX Therapeutics, an OPKO Health company, for the use of Nona’s platforms to support ModeX’s development of multispecific antibody therapeutics.

Under the terms of the agreement, ModeX will have access to Nona Bioscience’s fully human Harbour Mice® platforms to accelerate discovery of monoclonal antibodies to be integrated into ModeX’s MSTAR platform. This is intended to significantly reduce an often time-consuming step of the preclinical development process. The MSTAR platform is designed to layer multispecific functionality onto industry-standard antibody designs to enable a much wider range of functionality and disease applicability. The collaboration aims to leverage each company’s unique strengths to drive forward the discovery of cutting edge treatments.

“We are delighted to enter into this collaboration with ModeX Therapeutics,” Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences, said, “We believe that our discovery platforms are highly complementary to ModeX’s approach and are pleased to be able to offer a solution with the potential to speed the discovery of antibodies that ModeX can leverage in multispecific research and development.”

“We look forward to partnering with Nona Biosciences to accelerate and enhance our discovery of novel multispecific antibody constructs that our team can advance into clinical development,” said John Mascola, M.D., Chief Scientific Officer at ModeX.

  1. Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development Read more
  2. Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Read more
  3. Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia Read more
  4. Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis Read more
  5. Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency Read more